| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2009PLoSO...4.6682P |
| P356 | DOI | 10.1371/JOURNAL.PONE.0006682 |
| P932 | PMC publication ID | 2724683 |
| P698 | PubMed publication ID | 19690618 |
| P5875 | ResearchGate publication ID | 26751382 |
| P50 | author | Brian Greenwood | Q4963885 |
| Steffen Borrmann | Q30103006 | ||
| Akintunde Sowunmi | Q76590013 | ||
| Peter Winstanley | Q106879348 | ||
| Zul Premji | Q114316221 | ||
| Seth Owusu-Agyei | Q47007270 | ||
| P2093 | author name string | Stephen A Ward | |
| Stephan Duparc | |||
| Fabian Esamai | |||
| Stephen Oguche | |||
| Allan Pamba | |||
| Rich E Umeh | |||
| Paula L Kirby | |||
| Robert Guiguemdé | |||
| Emmanuel U Ezedinachi | |||
| Lynda Kellam | |||
| P2860 | cites work | The normal human female as a mosaic of X-chromosome activity: studies using the gene for C-6-PD-deficiency as a marker | Q24594299 |
| Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether | Q24792020 | ||
| Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria | Q28472247 | ||
| An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria | Q28473004 | ||
| High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency | Q28474365 | ||
| Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. | Q31043633 | ||
| Population study of common glucose-6-phosphate dehydrogenase mutations in Kuwait | Q77703313 | ||
| Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria | Q33978975 | ||
| Identification of a single base change in a new human mutant glucose-6-phosphate dehydrogenase gene by polymerase-chain-reaction amplification of the entire coding region from genomic DNA. | Q34120279 | ||
| Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial | Q34666104 | ||
| Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone | Q35827434 | ||
| Effect of expanded insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study | Q36226019 | ||
| Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. | Q36989259 | ||
| Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial | Q38399521 | ||
| Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial | Q38870092 | ||
| Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. | Q38883375 | ||
| A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria | Q38998772 | ||
| A comparative study of Lapudrine (chlorproguanil) and Maloprim (pyrimethamine and dapsone) as chemoprophylactics against malaria in Gambian children | Q39103241 | ||
| Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial | Q39284402 | ||
| At least five polymorphic mutants account for the prevalence of glucose-6-phosphate dehydrogenase deficiency in Algeria | Q39289655 | ||
| Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria | Q40510491 | ||
| The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency | Q40656977 | ||
| Maloprim malaria prophylaxis in children living in a holoendemic village in north-eastern Tanzania | Q40658843 | ||
| Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso | Q43932437 | ||
| Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania | Q43947607 | ||
| Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum | Q44167789 | ||
| Molecular epidemiology and activity of erythrocyte G6PD variants in a homogeneous Nigerian population | Q44179949 | ||
| Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-. | Q46577039 | ||
| High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria | Q46667800 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| Plasmodium falciparum | Q311383 | ||
| artesunate | Q707939 | ||
| lumefantrine | Q904464 | ||
| teenager | Q1492760 | ||
| Plasmodium falciparum malaria | Q18554672 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | e6682 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria | |
| P478 | volume | 4 |
| Q38772466 | A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications |
| Q98946693 | A Study on the Relevance of Glucose-6-Phosphate Dehydrogenase Level Screening in Patients with Rheumatic Diseases Prior to Initiating Treatment With Hydroxychloroquine |
| Q28477853 | A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial |
| Q34020818 | A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmission |
| Q41935621 | Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum |
| Q39402508 | Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum |
| Q34267667 | Artemether-lumefantrine: an option for malaria |
| Q30995133 | Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis |
| Q34273825 | Changing malaria intervention coverage, transmission and hospitalization in Kenya |
| Q35029488 | Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review |
| Q38895510 | Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis |
| Q57274839 | Estado actual de la malaria (I): diagnóstico y tratamiento |
| Q38303998 | Evolution from double to triple-antimalarial drug combinations |
| Q28478215 | Fitness trade-offs in the evolution of dihydrofolate reductase and drug resistance in Plasmodium falciparum |
| Q33726415 | Formation and identification of a degradant in chlorproguanil–dapsone–artesunate (Dacart™) tablets |
| Q35283214 | Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials |
| Q27005605 | G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications |
| Q37641492 | Gancidin W, a potential low-toxicity antimalarial agent isolated from an endophytic Streptomyces SUK10 |
| Q28547654 | Glucose-6-Phosphate Dehydrogenase Deficiency and Haemoglobin Drop after Sulphadoxine-Pyrimethamine Use for Intermittent Preventive Treatment of Malaria during Pregnancy in Ghana - A Cohort Study |
| Q28265711 | Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria |
| Q34058341 | Glucose-6-phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum-infected African children receiving single-dose primaquine |
| Q34478487 | Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines |
| Q34433106 | Malaria: an update on current chemotherapy |
| Q28468598 | New developments in anti-malarial target candidate and product profiles |
| Q36055205 | PharmGKB summary: very important pharmacogene information for G6PD. |
| Q34977413 | Pharmacogenomics of antimicrobial agents |
| Q53701213 | Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. |
| Q35031434 | Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia |
| Q35850290 | Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants |
| Q38957310 | Role of Preemptive Genotyping in Preventing Serious Adverse Drug Events in South Korean Patients. |
| Q35821563 | Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children |
| Q28286833 | The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics |
| Q38673925 | Triple Combination Therapy and Drug Cycling-Tangential Strategies for Countering Artemisinin Resistance |
| Q34284211 | Use of Area Under the Curve to Evaluate the Effects of Antimalarial Drugs on Malaria-Associated Anemia After Treatment |
Search more.